{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:16:33Z","timestamp":1791832593607,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.tips.2023.09.010","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T16:08:36Z","timestamp":1698077316000},"page":"869-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Glaucoma: neuroprotection with NAD-based therapeutic interventions"],"prefix":"10.1016","volume":"44","author":[{"given":"Alberto","family":"Chiarugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2023.09.010_bb0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/IJG.0000000000002248","article-title":"A systematic review of glaucoma diagnosis in prevalence studies and quality of reporting","volume":"32","author":"Al-Timimi","year":"2023","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.tips.2023.09.010_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-vision-102016-061422","article-title":"Neuroprotection in glaucoma: animal models and clinical trials","volume":"3","author":"Almasieh","year":"2017","journal-title":"Annu. Rev. Vis. Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101193","article-title":"Neuroprotection in glaucoma: mechanisms beyond intraocular pressure lowering","volume":"92","author":"Tribble","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tips.2023.09.010_bb0020","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/IJG.0000000000000767","article-title":"Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma","volume":"26","author":"Williams","year":"2017","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.tips.2023.09.010_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/IJG.0000000000000949","article-title":"Distribution and progression of visual field defects with binocular vision in glaucoma","volume":"27","author":"Hashimoto","year":"2018","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.tips.2023.09.010_bb0030","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1083\/jcb.200706181","article-title":"Axons of retinal ganglion cells are insulted in the optic nerve early in DBA\/2J glaucoma","volume":"179","author":"Howell","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tips.2023.09.010_bb0035","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1523\/JNEUROSCI.4694-06.2007","article-title":"Roles of volume-sensitive chloride channel in excitotoxic neuronal injury","volume":"27","author":"Inoue","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2023.09.010_bb0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.expneurol.2012.01.014","article-title":"Intrinsic axonal degeneration pathways are critical for glaucomatous damage","volume":"246","author":"Howell","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2023.09.010_bb0045","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.3390\/ijms23158068","article-title":"Remodeling of the lamina cribrosa: mechanisms and potential therapeutic approaches for glaucoma","volume":"23","author":"Strickland","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0050","first-page":"771","article-title":"Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve","volume":"13","author":"Anderson","year":"1974","journal-title":"Investig. Ophthalmol."},{"key":"10.1016\/j.tips.2023.09.010_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF02174064","article-title":"Blockage at two points of axonal transport in glaucomatous eyes","volume":"223","author":"Sakugawa","year":"1985","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.tips.2023.09.010_bb0060","doi-asserted-by":"crossref","first-page":"C611","DOI":"10.1152\/ajpcell.00054.2020","article-title":"The role of lamina cribrosa tissue stiffness and fibrosis as fundamental biomechanical drivers of pathological glaucoma cupping","volume":"319","author":"Hopkins","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tips.2023.09.010_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02713683.2022.2039204","article-title":"Glaucoma - \u2018a stiff eye in a stiff body\u2019","volume":"48","author":"Powell","year":"2023","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0070","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.preteyeres.2012.07.001","article-title":"Critical pathogenic events underlying progression of neurodegeneration in glaucoma","volume":"31","author":"Calkins","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108682","article-title":"Mechanisms of organelle elimination for lens development and differentiation","volume":"209","author":"Brennan","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.preteyeres.2013.07.001","article-title":"Retinal ganglion cells: energetics, compartmentation, axonal transport, cytoskeletons and vulnerability","volume":"36","author":"Yu","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0085","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/cells12172131","article-title":"Astrocytes in the optic nerve are heterogeneous in their reactivity to glaucomatous injury","volume":"12","author":"Zhu","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tips.2023.09.010_bb0090","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/cells10061368","article-title":"Astrocyte networks as therapeutic targets in glaucomatous neurodegeneration","volume":"10","author":"Boal","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.tips.2023.09.010_bb0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-neuro-060909-153248","article-title":"Wallerian degeneration, wld(s), and nmnat","volume":"33","author":"Coleman","year":"2010","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.tips.2023.09.010_bb0100","doi-asserted-by":"crossref","first-page":"9717","DOI":"10.1073\/pnas.90.20.9717","article-title":"A gene affecting Wallerian nerve degeneration maps distally on mouse chromosome 4","volume":"90","author":"Lyon","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.09.010_bb0105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/iub.2584","article-title":"The key role of the NAD biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase in regulating cell functions","volume":"74","author":"Fortunato","year":"2022","journal-title":"IUBMB Life"},{"key":"10.1016\/j.tips.2023.09.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102176","article-title":"The chemical biology of NAD(+) regulation in axon degeneration","volume":"69","author":"Icso","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.tips.2023.09.010_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41583-020-0269-3","article-title":"Programmed axon degeneration: from mouse to mechanism to medicine","volume":"21","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2023.09.010_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.conb.2020.02.012","article-title":"The SARM1 axon degeneration pathway: control of the NAD(+) metabolome regulates axon survival in health and disease","volume":"63","author":"Figley","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tips.2023.09.010_bb0125","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.molcel.2022.03.007","article-title":"Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules","volume":"82","author":"Shi","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2023.09.010_bb0130","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.neuron.2021.02.009","article-title":"SARM1 is a metabolic sensor activated by an increased NMN\/NAD(+) ratio to trigger axon degeneration","volume":"109","author":"Figley","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2023.09.010_bb0135","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/cdd.2014.164","article-title":"A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration","volume":"22","author":"Di Stefano","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2023.09.010_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtn.2023.02.029","article-title":"Differential effects of SARM1 inhibition in traumatic glaucoma and EAE optic neuropathies","volume":"32","author":"Liu","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2023.09.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.201912047","article-title":"SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration","volume":"219","author":"Ko","year":"2020","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tips.2023.09.010_bb0150","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2023.09.010_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnins.2017.00232","article-title":"Nicotinamide and WLD(S) act together to prevent neurodegeneration in glaucoma","volume":"11","author":"Williams","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2023.09.010_bb0160","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/pharmaceutics13060893","article-title":"Systemic treatment with nicotinamide riboside is protective in two mouse models of retinal ganglion cell damage","volume":"13","author":"Zhang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tips.2023.09.010_bb0165","doi-asserted-by":"crossref","first-page":"33619","DOI":"10.1073\/pnas.2014213117","article-title":"Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin","volume":"117","author":"Harder","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.09.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115644","article-title":"Identification of the first noncompetitive SARM1 inhibitors","volume":"28","author":"Loring","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2023.09.010_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108588","article-title":"Small molecule SARM1 inhibitors recapitulate the SARM1(-\/-) phenotype and allow recovery of a metastable pool of axons fated to degenerate","volume":"34","author":"Hughes","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2023.09.010_bb0180","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1016\/j.neuron.2022.08.017","article-title":"Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease","volume":"110","author":"Bratkowski","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2023.09.010_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00018-023-04701-2","article-title":"Correction: A duplex structure of SARM1 octamers stabilized by a new inhibitor","volume":"80","author":"Khazma","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ptr.7594","article-title":"The therapeutic potential of berberine chloride against SARM1-dependent axon degeneration in acrylamide-induced neuropathy","volume":"37","author":"Wang","year":"2023","journal-title":"Phytother. Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neures.2023.01.004","article-title":"NMN: the NAD precursor at the intersection between axon degeneration and anti-ageing therapies","author":"Loreto","year":"2023","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.tips.2023.09.010_bb0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial","volume":"48","author":"Hui","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.tips.2023.09.010_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamaophthalmol.2021.4576","article-title":"Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial","volume":"140","author":"De Moraes","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tips.2023.09.010_bb0210","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/nu13124263","article-title":"Association between daily niacin intake and glaucoma: national health and nutrition examination survey","volume":"13","author":"Taechameekietichai","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.tips.2023.09.010_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13063-021-05968-1","article-title":"Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial","volume":"23","author":"Leung","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.tips.2023.09.010_bb0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40478-023-01513-0","article-title":"NAD salvage pathway machinery expression in normal and glaucomatous retina and optic nerve","volume":"11","author":"Tribble","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.tips.2023.09.010_bb0225","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/antiox11091637","article-title":"Current uncertainties and future challenges regarding NAD+ boosting strategies","volume":"11","author":"Poljsak","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.tips.2023.09.010_bb0230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/agm2.12184","article-title":"Nicotinamide adenine dinucleotide and the sirtuins caution: pro-cancer functions","volume":"4","author":"Palmer","year":"2021","journal-title":"Aging Med. (Milton)"},{"key":"10.1016\/j.tips.2023.09.010_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114826","article-title":"A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD(+) metabolism","volume":"220","author":"Maric","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.tips.2023.09.010_bb0240","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1349-7006.2007.00567.x","article-title":"PolyADP-ribosylation and cancer","volume":"98","author":"Miwa","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109516","article-title":"NAD(+) supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2023.09.010_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658263","article-title":"The key role of NAD(+) in anti-tumor immune response: an update","volume":"12","author":"Morandi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.09.010_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2023.09.010_bb0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/2772434416666211129105629","article-title":"Cosmeceutical aptitudes of niacinamide: a review","volume":"16","author":"Madaan","year":"2021","journal-title":"Recent Adv. Antiinfect. Drug Discov."},{"key":"10.1016\/j.tips.2023.09.010_bb0265","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2023.09.010_bb0270","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41433-022-02036-z","article-title":"Oral nicotinamide for non-melanoma skin cancers: a review","volume":"37","author":"Hunt","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.tips.2023.09.010_bb0275","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2023.09.010_bb0280","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62027","article-title":"SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration","volume":"9","author":"Sasaki","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.tips.2023.09.010_bb0285","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900618","article-title":"SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration","volume":"3","author":"Ozaki","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.tips.2023.09.010_bb0290","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/nu12092871","article-title":"Potential therapeutic benefit of NAD(+) supplementation for glaucoma and age-related macular degeneration","volume":"12","author":"Cimaglia","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.tips.2023.09.010_bb0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrn2229","article-title":"Pathologically activated therapeutics for neuroprotection","volume":"8","author":"Lipton","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2023.09.010_bb0300","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.tips.2023.09.010_bb0305","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1167\/iovs.03-0567","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0310","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1167\/iovs.03-0566","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tips.2023.09.010_bb0315","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00061198-200212000-00003","article-title":"Neuroprotective effect of memantine in different retinal injury models in rats","volume":"11","author":"WoldeMussie","year":"2002","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.tips.2023.09.010_bb0320","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S0039-6257(01)00200-4","article-title":"Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey","volume":"45","author":"Hare","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.tips.2023.09.010_bb0325","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:15:06Z","timestamp":1759050906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614723002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0165614723002122"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2023.09.010","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glaucoma: neuroprotection with NAD-based therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2023.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}